[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kanaya et al., 2023 - Google Patents

Gene-edited and-engineered stem cell platform drives immunotherapy for brain metastatic melanomas

Kanaya et al., 2023

View HTML
Document ID
446669018174504505
Author
Kanaya N
Kitamura Y
Lopez Vazquez M
Franco A
Chen K
van Schaik T
Farzani T
Borges P
Ichinose T
Seddiq W
Kuroda S
Boland G
Jahan N
Fisher D
Wakimoto H
Shah K
Publication year
Publication venue
Science translational medicine

External Links

Snippet

Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first …
Continue reading at www.science.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
LaFleur et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
Ye et al. In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma
Walle et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
Pavel-Dinu et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells
Saha et al. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma
ES2942210T3 (en) Non-integrative DNA vectors for genetic modification of cells
Caretti et al. Human pontine glioma cells can induce murine tumors
Potts et al. Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models
Malouli et al. Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy
Yin et al. Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy
Kanaya et al. Gene-edited and-engineered stem cell platform drives immunotherapy for brain metastatic melanomas
JP2017514471A (en) Chimeric antigen receptor (CAR) and method for producing and using the same
Sahu et al. Rat and mouse brain tumor models for experimental neuro-oncology research
Jahan et al. In situ cancer vaccination and immunovirotherapy using oncolytic HSV
WO2018191440A1 (en) In vivo gene editing of blood progenitors
CN106220736A (en) A kind of Chimeric antigen receptor, the cell expressing it and its production and use
JP2023501590A (en) Therapy for hematopoietic cell malignancies using genetically engineered T cells that target CD70
Yang et al. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
Lee et al. The endogenous repertoire harbors self-reactive CD4+ T cell clones that adopt a follicular helper T cell-like phenotype at steady state
Wang et al. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
Pires‐Afonso et al. Elucidating tumour‐associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency
Benedetti et al. A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development
Yang et al. Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS
Chuntova et al. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice
Kararoudi et al. CRISPR-targeted CAR gene insertion using Cas9/RNP and AAV6 enhances anti-AML activity of primary NK cells